158 related articles for article (PubMed ID: 8967966)
1. Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180).
Cornarotti M; Tinelli S; Willmore E; Zunino F; Fisher LM; Austin CA; Capranico G
Mol Pharmacol; 1996 Dec; 50(6):1463-71. PubMed ID: 8967966
[TBL] [Abstract][Full Text] [Related]
2. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
3. Genomic sites of topoisomerase II activity determined by comparing DNA breakage enhanced by three distinct poisons.
Borgnetto ME; Tinelli S; Carminati L; Capranico G
J Mol Biol; 1999 Jan; 285(2):545-54. PubMed ID: 9878428
[TBL] [Abstract][Full Text] [Related]
4. Drug-specific sites of topoisomerase II DNA cleavage in Drosophila chromatin: heterogeneous localization and reversibility.
Borgnetto ME; Zunino F; Tinelli S; Kas E; Capranico G
Cancer Res; 1996 Apr; 56(8):1855-62. PubMed ID: 8620504
[TBL] [Abstract][Full Text] [Related]
5. Position-specific effects of base mismatch on mammalian topoisomerase II DNA cleaving activity.
Bigioni M; Zunino F; Tinelli S; Austin CA; Willmore E; Capranico G
Biochemistry; 1996 Jan; 35(1):153-9. PubMed ID: 8555169
[TBL] [Abstract][Full Text] [Related]
6. Human DNA topoisomerase IIalpha-dependent DNA cleavage and yeast cell killing by anthracycline analogues.
Binaschi M; Farinosi R; Austin CA; Fisher LM; Zunino F; Capranico G
Cancer Res; 1998 May; 58(9):1886-92. PubMed ID: 9581829
[TBL] [Abstract][Full Text] [Related]
7. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
8. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
[TBL] [Abstract][Full Text] [Related]
9. In vivo site specificity and human isoenzyme selectivity of two topoisomerase II-poisoning anthracyclines.
Binaschi M; Farinosi R; Borgnetto ME; Capranico G
Cancer Res; 2000 Jul; 60(14):3770-6. PubMed ID: 10919649
[TBL] [Abstract][Full Text] [Related]
10. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
11. Change of the sequence specificity of daunorubicin-stimulated topoisomerase II DNA cleavage by epimerization of the amino group of the sugar moiety.
Capranico G; Butelli E; Zunino F
Cancer Res; 1995 Jan; 55(2):312-7. PubMed ID: 7812964
[TBL] [Abstract][Full Text] [Related]
12. Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage.
Capranico G; Palumbo M; Tinelli S; Mabilia M; Pozzan A; Zunino F
J Mol Biol; 1994 Jan; 235(4):1218-30. PubMed ID: 8308885
[TBL] [Abstract][Full Text] [Related]
13. DNA sequence specificity for topoisomerase II poisoning by the quinoxaline anticancer drugs XK469 and CQS.
Gao H; Yamasaki EF; Chan KK; Shen LL; Snapka RM
Mol Pharmacol; 2003 Jun; 63(6):1382-8. PubMed ID: 12761349
[TBL] [Abstract][Full Text] [Related]
14. Quinolone action against human topoisomerase IIalpha: stimulation of enzyme-mediated double-stranded DNA cleavage.
Bromberg KD; Burgin AB; Osheroff N
Biochemistry; 2003 Apr; 42(12):3393-8. PubMed ID: 12653542
[TBL] [Abstract][Full Text] [Related]
15. Characterization of DNA topoisomerase II alpha/beta heterodimers in HeLa cells.
Gromova I; Biersack H; Jensen S; Nielsen OF; Westergaard O; Andersen AH
Biochemistry; 1998 Nov; 37(47):16645-52. PubMed ID: 9843432
[TBL] [Abstract][Full Text] [Related]
16. Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: expression of a functional recombinant human DNA topoisomerase II alpha in yeast.
Wasserman RA; Austin CA; Fisher LM; Wang JC
Cancer Res; 1993 Aug; 53(15):3591-6. PubMed ID: 8393377
[TBL] [Abstract][Full Text] [Related]
17. Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity.
Mao Y; Yu C; Hsieh TS; Nitiss JL; Liu AA; Wang H; Liu LF
Biochemistry; 1999 Aug; 38(33):10793-800. PubMed ID: 10451375
[TBL] [Abstract][Full Text] [Related]
18. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
19. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.
De Isabella P; Capranico G; Palumbo M; Sissi C; Krapcho AP; Zunino F
Mol Pharmacol; 1993 May; 43(5):715-21. PubMed ID: 8388987
[TBL] [Abstract][Full Text] [Related]
20. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
Spitzner JR; Chung IK; Gootz TD; McGuirk PR; Muller MT
Mol Pharmacol; 1995 Aug; 48(2):238-49. PubMed ID: 7651357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]